Cell & Gene Exchange, May 2017: Généthon

June 16, 2017
Généthon, created by the AFM-Telethon, is dedicated to making innovative gene therapy treatments available to patients affected with rare genetic diseases. Having played a pioneering role in deciphering the human genome, Généthon is today, with more than 120 scientists, physicians, engineers and regulatory affairs specialists, one of the leading organizations for the development of gene therapy treatments. Généthon has also built one of the largest sites worldwide for GMP-production of gene therapy products, that was incorporated in 2016 into YposKesi, a company created with the investment of AFM-Telethon and BPI-France, in order to address the challenges of industrializing cell and gene therapy methods. Généthon was awarded the prestigious Prix Galien for Pharmaceutical Research (France) in 2012. In 2015, Genethon was one of 16 winners of the World Innovation Competition 2030 for its project on the development of an industrial process for production of gene therapy vectors. The pipeline of Généthon includes products currently in international clinical trials and at preclinical stages, for immune deficiencies, muscular dystrophies, blood and liver diseases. These products are developed either with Généthon as sponsor, or in partnership with private companies and academic institutions. www.genethon.com Speaker: Revah Frédéric – CEO
Previous Video
Cell & Gene Exchange, May 2017: MEDIPOST America
Cell & Gene Exchange, May 2017: MEDIPOST America

MEDIPOST develops allogeneic stem cell products using multi-potent human Umbilical Cord Blood-derived Mesen...

Next Video
Cell & Gene Exchange, May 2017: bBHC-STRI
Cell & Gene Exchange, May 2017: bBHC-STRI

The STC Stem Cell Treatment & Research Institute-bBHC developed the pluripotent stem cell free from side ef...